Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2026-07-09 18:04:18 ET · period of report 2026-07-07 · accession 0001856094-26-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-09 18:04 | 2026-07-07 | RXRX | Borgeson Blake | Dir | S - Sale | $3.96 | -40.0K | 6.22M | -0.6% | -$158.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-07-07 | S | D | 40,000 | $3.96 | 6,218,287 | D | — | — | (F1) This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $3.95 to $4.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |